Your missing links are here

Top picks

• UK Scientists CRISPR-edited human embryos in the lab, and the experiment went horribly wrong. The study posted on a preprint server bioRxiv on June 5 raises major safety concerns for gene-edited babies.
• Nature news adds more: »CRISPR gene editing in human embryos wreaks chromosomal mayhem«.
• A year in, 1st patient to get gene editing for Sickle Cell Disease is thriving. And here is our story on the new data from the landmark CRISPR-Cas9 gene-editing clinical trial.

Research

• CHANGE-seq, a high-throughput and straightforward approach to understanding the specificity of genome editors.
• Guide-free Cas9 from pathogenic Campylobacter jejuni bacteria plays an active role in attacking human cells rather than in viral defence.
• CRISPR-Cas9 Gene Editing may correct genetic defect in DEB, study suggests.
• Nature-Inspired CRISPR Enzyme discoveries vastly expand genome editing.
• Human stem cells and CRISPR are used to identify degeneration targets that may lead to novel therapeutic approaches for glaucoma.
• Muscle finding could lead to new therapies for heart disease and skeletal muscle disorders.
• Method to combat Parkinson’s disease by astrocyte-to-neuron conversion.
• Multitasking for base editors.

Reviews

• Nature Biotechnology Review from the Liu Lab on the new CRISPR-Cas genome editing tools like base- and prime-editors, and key considerations for choosing genome editing agents.

COVID19

• UC Riverside engineers are using supercomputers to investigate rapid, CRISPR-based COVID-19 tests.
• CRISPR-Cas9 screen reveals host genes that aid SARS-CoV-2 infection. The discovery could assist in the development of new therapies, and reveal why some people are more susceptible to COVID-19 than others.
• How medicine makers personal and professional lives have changed over the course of the COVID-19 crisis. Featuring Simon Tyler at CatSci, Nick Shackley at Johnson Matthey, Chris Lowe at Horizon Discovery, and Andrew Bulpin at Merck.

Clinical trials

• Editas Medicine presents pre-clinical data from a study of EDIT-301 with Sickle Patient Cells for the potential treatment of Sickle Cell Disease.
• CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress.

Vision and opinion

• World Economic Forum 17 bids on how technology could change the world by 2025, including from Rahul Dhanda, Co-Founder and CEO of Sherlock Biosciences. »Engineering biology, machine learning and the sharing economy will establish a framework for decentralising the healthcare continuum, moving it from institutions to the individual.« We recently interviewed Dhanda about the first-ever FDA-approved CRISPR kit for COVID19 detection.

• The Conversation: Gene therapy and CRISPR strategies for curing blindness (Yes, you read that right).

Industry

• CRISPR Therapeutics is joining the rush to build new cell therapy manufacturing space.
• From academia to start-up. Stefano Stella talks about taking groundbreaking CRISPR research to investors for the Cas12a start-up Twelve Bio he co-founded. Stella recently gave us an interview on Cas12a and Twelve Bio here.
• Verve banks $63M to move gene-editing heart attack treatment toward the clinic.
• Exosome delivery tech in $72.5M neuromuscular disease deal.

Heh, huh, wow

• Meet the family working with scientists to fight rare diseases with CRISPR therapy. Video [04:43 min].

Reminder: 50% discount on CRISPR Medicine News: You may take advantage of this discount using the promo code: CMN2020 when you follow this link: https://crisprmedicinenews.com/index.php?id=1250&no_cache=1

The deadline for the 50% offer is 1^st August 2020.

Remember, all students have free access to all content on CRISPR Medicine News. Our newsletter will also stay free, and new articles will be open to read for the first three days.

Thank You for now.

And if you have questions or suggestions, you can directly reach us at editor@crisprmedicinenews.com. We love hearing from readers!

(c; Rasmus

You can follow the blog on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up yourself here.